BOSTON and PETACH TIKVA, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, today announced an exclusive distribution agreement for Medison to commercialize Rhythm’s melanocortin-4 (MC4) receptor agonist IMCIVREE™ (setmelanotide) in Israel.
IMCIVREE was approved on November 2020 by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing.
“We are committed to delivering IMCIVREE to people living with rare genetic diseases of obesity around the world, and we believe Medison will be a strong partner as we extend our commercial footprint into Israel,” said Yann Mazabraud, Rhythm’s Executive Vice President and Head of International. “Medison has a robust platform and a track record of successfully advancing programs through the registration and reimbursement processes, and we look forward to working together to bring IMCIVREE to patients with POMC, PCSK1 and LEPR deficiency obesity.”
“Our partnership with Rhythm reflects our shared commitment to improving the lives of patients who suffer from life-threatening, rare genetic diseases through highly innovative therapies”, said Meir Jakobsohn, Founder and CEO of Medison Pharma. “IMCIVREE perfectly fits in our portfolio of novel medicines, and we look forward to providing patients and physicians with this much-needed treatment”.
For the complete press release: https://www.globenewswire.com